Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

Callan Capital LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 49,425 shares of the company's stock, valued at approximately $735,000.

Several other institutional investors have also recently modified their holdings of TAK. First Trust Advisors LP increased its position in Takeda Pharmaceutical by 2.0% during the fourth quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after buying an additional 62,718 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after acquiring an additional 238,161 shares during the last quarter. Soleus Capital Management L.P. increased its position in Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock worth $15,623,000 after purchasing an additional 680,000 shares in the last quarter. Summit Global Investments increased its position in Takeda Pharmaceutical by 75.5% during the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after purchasing an additional 313,642 shares in the last quarter. Finally, Toronto Dominion Bank acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $6,760,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.8%

Shares of TAK traded up $0.12 on Wednesday, hitting $15.14. 1,629,468 shares of the stock traded hands, compared to its average volume of 1,992,140. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $16.00. The stock's 50 day moving average is $14.86 and its two-hundred day moving average is $14.35. The firm has a market capitalization of $48.17 billion, a P/E ratio of 9.51 and a beta of 0.23. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. As a group, sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.